MA27675A1 - PIPERAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES - Google Patents
PIPERAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASESInfo
- Publication number
- MA27675A1 MA27675A1 MA28564A MA28564A MA27675A1 MA 27675 A1 MA27675 A1 MA 27675A1 MA 28564 A MA28564 A MA 28564A MA 28564 A MA28564 A MA 28564A MA 27675 A1 MA27675 A1 MA 27675A1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- neurological
- piperazine derivatives
- psychiatric diseases
- psychiatric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
DERIVES DE PIPERAZINE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES NEUROLOGIQUES ET PSYCHIATRIQUES La présente invention concerne des dérivés de pipéridine-carbonyl-pipérazine nouveaux ayant une activité pharmacologique, des procédés pour leur préparation, des compositions les contenant et leur utilisation dans le traitement de troubles neurologiques et psychiatriques.The present invention relates to novel piperidine-carbonyl-piperazine derivatives having pharmacological activity, processes for their preparation, compositions containing them and their use in the treatment of disorders neurological and psychiatric.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0309222A GB0309222D0 (en) | 2003-04-23 | 2003-04-23 | Novel compounds |
GB0323109A GB0323109D0 (en) | 2003-10-02 | 2003-10-02 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27675A1 true MA27675A1 (en) | 2005-12-01 |
Family
ID=33454571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28564A MA27675A1 (en) | 2003-04-23 | 2005-10-19 | PIPERAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES |
Country Status (24)
Country | Link |
---|---|
US (1) | US7592347B2 (en) |
EP (1) | EP1615909B1 (en) |
JP (1) | JP2006528939A (en) |
KR (1) | KR20050121268A (en) |
AR (1) | AR044045A1 (en) |
AT (1) | ATE402165T1 (en) |
AU (1) | AU2004238447C1 (en) |
BR (1) | BRPI0409611A (en) |
CA (1) | CA2523431A1 (en) |
CO (1) | CO5700754A2 (en) |
DE (1) | DE602004015269D1 (en) |
DK (1) | DK1615909T3 (en) |
ES (1) | ES2311152T3 (en) |
HK (1) | HK1090634A1 (en) |
HR (1) | HRP20080541T3 (en) |
IS (1) | IS8134A (en) |
MA (1) | MA27675A1 (en) |
MX (1) | MXPA05011352A (en) |
PL (1) | PL1615909T3 (en) |
PT (1) | PT1615909E (en) |
RU (1) | RU2005136368A (en) |
SI (1) | SI1615909T1 (en) |
TW (1) | TW200503713A (en) |
WO (1) | WO2004101546A1 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
AU2005259947A1 (en) | 2004-06-28 | 2006-01-12 | Hutta, Daniel A. | Hetero isonipecotic modulators of vanilloid VR1 receptor |
SI1802307T1 (en) * | 2004-10-15 | 2008-08-31 | Glaxo Group Ltd | Pyrrolidine derivatives as histamine receptors ligands |
US7635705B2 (en) | 2005-06-20 | 2009-12-22 | Schering Corporation | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists |
MX2007016523A (en) | 2005-06-20 | 2008-03-06 | Schering Corp | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists. |
CA2607499C (en) | 2005-06-22 | 2010-11-30 | Pfizer Products Inc. | Histamine-3 receptor antagonists |
EP1909797A4 (en) * | 2005-08-02 | 2013-02-27 | Neurogen Corp | Dipiperazinyl ketones and related analogues |
EP1931665A1 (en) | 2005-09-20 | 2008-06-18 | Schering Corporation | 1-[[1-[(2-amin0-6-methyl-4-pyridinyl)methyl]-4-flu0r0-4-piperidinyl,]carbonyl]-4-[2-(2-pyridinyl)-3h-imidaz0[4, 5-b]pyridin-3-yl]piperidine useful as histamine h3 antagonist |
MX2008008337A (en) | 2005-12-21 | 2008-09-03 | Schering Corp | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists. |
PE20071136A1 (en) | 2005-12-21 | 2007-12-29 | Schering Corp | DERIVATIVES OF ANILINE SUBSTITUTED AS ANTAGONISTS OF HISTAMINE H3 |
AU2007260836B2 (en) | 2006-06-23 | 2012-11-15 | Abbvie Bahamas Ltd. | Cyclopropyl amine derivatives as histamin H3 receptor modulators |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
CN101674831A (en) * | 2007-03-02 | 2010-03-17 | 先灵公司 | Piperidine derivatives and methods of use thereof |
TW200902007A (en) * | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
CA2687931C (en) * | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
ATE481395T1 (en) | 2007-06-11 | 2010-10-15 | Hoffmann La Roche | CYCLOHEXYL DERIVATIVES |
CN101835750B (en) | 2007-08-22 | 2013-07-17 | 阿斯利康(瑞典)有限公司 | Cyclopropyl amide derivatives '978 |
ATE554081T1 (en) | 2007-09-06 | 2012-05-15 | Glaxo Group Ltd | PIPERAZINE DERIVATIVES WITH AFFINITY FOR HISTAMINE H3 RECEPTOR |
US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
PE20120061A1 (en) | 2008-12-19 | 2012-02-19 | Boehringer Ingelheim Int | PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR2 RECEPTOR |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
PT3091012T (en) | 2009-12-17 | 2018-06-27 | Centrexion Therapeutics Corp | Ccr2 receptor antagonists and uses thereof |
BR112012020629A2 (en) | 2010-02-18 | 2018-06-19 | Astrazeneca Ab | crystalline form and method for the therapy of a disorder |
BR112012020780A2 (en) * | 2010-02-18 | 2016-05-03 | Astrazeneca Ab | solid form, pharmaceutical composition, and, use of a solid form. |
US8946218B2 (en) | 2010-05-12 | 2015-02-03 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
JP2013526507A (en) | 2010-05-12 | 2013-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | NOVEL CCR2 RECEPTOR ANTAGONIST, PROCESS FOR PRODUCING THE SAME AND USE THEREOF AS DRUG |
US8841313B2 (en) | 2010-05-17 | 2014-09-23 | Boehringer Ingelheim International Gmbh | CCR2 antagonists and uses thereof |
JP5636094B2 (en) | 2010-05-25 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | CCR2 receptor antagonist |
EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
JP5786258B2 (en) | 2011-07-15 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel and selective CCR2 antagonist |
AR088256A1 (en) | 2011-10-08 | 2014-05-21 | Novartis Ag | CARBAMATE / UREA DERIVATIVES AS H3 RECEIVER ANTAGONISTS |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
MX2017017177A (en) | 2015-07-02 | 2018-11-09 | Centrexion Therapeutics Corp | (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)pi peridin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro- 2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate. |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364791A (en) * | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
ATE365209T1 (en) * | 1992-05-14 | 2007-07-15 | Baylor College Medicine | MUTATED STEROID HORMONE RECEPTORS, METHODS FOR THEIR USE AND MOLECULAR SWITCH FOR GENE THERAPY |
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
NZ325248A (en) | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
WO1998006705A1 (en) * | 1996-08-14 | 1998-02-19 | Zeneca Limited | Substituted pyrimidine derivatives and their pharmaceutical use |
CA2320730A1 (en) * | 1998-12-23 | 2000-07-06 | Renhua Li | Thrombin or factor xa inhibitors |
US6683093B2 (en) * | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
PE20020507A1 (en) | 2000-10-17 | 2002-06-25 | Schering Corp | NON-IMIDAZOLE COMPOUNDS AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR |
AU2002231098A1 (en) * | 2000-12-15 | 2002-06-24 | Emory University | Nonpeptide agonists and antagonists of vasopressin receptors |
US6849621B2 (en) | 2001-03-13 | 2005-02-01 | Schering Corporation | Piperidine compounds |
AU2002254114A1 (en) | 2001-03-23 | 2002-10-08 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
EP1421071B1 (en) | 2001-07-02 | 2009-11-18 | High Point Pharmaceuticals, LLC | Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators |
JP2005508907A (en) | 2001-09-14 | 2005-04-07 | ノボ ノルディスク アクティーゼルスカブ | Substituted piperidine that selectively binds to the histamine H3 receptor |
WO2003024928A2 (en) | 2001-09-14 | 2003-03-27 | Novo Nordisk A/S | Novel aminoazetidine, -pyrrolidine and -piperidine derivatives |
JPWO2003062234A1 (en) | 2002-01-23 | 2005-05-19 | 山之内製薬株式会社 | Quinoxaline compounds |
NZ535763A (en) | 2002-04-18 | 2007-06-29 | Schering Corp | (1-4-piperidinyl) benzimidazole derivatives useful as histamine H3 antagonists |
MY132566A (en) | 2002-04-18 | 2007-10-31 | Schering Corp | Benzimidazolone histamine h3 antagonists |
JP2006512404A (en) | 2002-10-22 | 2006-04-13 | グラクソ グループ リミテッド | Aryloxyalkylamine derivatives as H3 receptor ligands |
-
2004
- 2004-04-21 EP EP04728561A patent/EP1615909B1/en not_active Expired - Lifetime
- 2004-04-21 CA CA002523431A patent/CA2523431A1/en not_active Abandoned
- 2004-04-21 PL PL04728561T patent/PL1615909T3/en unknown
- 2004-04-21 AU AU2004238447A patent/AU2004238447C1/en not_active Expired - Fee Related
- 2004-04-21 MX MXPA05011352A patent/MXPA05011352A/en active IP Right Grant
- 2004-04-21 AR ARP040101348A patent/AR044045A1/en not_active Application Discontinuation
- 2004-04-21 DK DK04728561T patent/DK1615909T3/en active
- 2004-04-21 PT PT04728561T patent/PT1615909E/en unknown
- 2004-04-21 BR BRPI0409611-8A patent/BRPI0409611A/en not_active IP Right Cessation
- 2004-04-21 US US10/553,803 patent/US7592347B2/en not_active Expired - Fee Related
- 2004-04-21 ES ES04728561T patent/ES2311152T3/en not_active Expired - Lifetime
- 2004-04-21 JP JP2006529693A patent/JP2006528939A/en active Pending
- 2004-04-21 SI SI200430886T patent/SI1615909T1/en unknown
- 2004-04-21 DE DE602004015269T patent/DE602004015269D1/en not_active Expired - Lifetime
- 2004-04-21 KR KR1020057019965A patent/KR20050121268A/en not_active Application Discontinuation
- 2004-04-21 RU RU2005136368/04A patent/RU2005136368A/en not_active Application Discontinuation
- 2004-04-21 AT AT04728561T patent/ATE402165T1/en not_active IP Right Cessation
- 2004-04-21 WO PCT/EP2004/004245 patent/WO2004101546A1/en active IP Right Grant
- 2004-04-21 TW TW093111027A patent/TW200503713A/en unknown
-
2005
- 2005-10-19 MA MA28564A patent/MA27675A1/en unknown
- 2005-10-21 CO CO05106973A patent/CO5700754A2/en not_active Application Discontinuation
- 2005-11-21 IS IS8134A patent/IS8134A/en unknown
-
2006
- 2006-06-30 HK HK06107421.8A patent/HK1090634A1/en not_active IP Right Cessation
-
2008
- 2008-10-23 HR HR20080541T patent/HRP20080541T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA05011352A (en) | 2005-11-28 |
PL1615909T3 (en) | 2009-01-30 |
EP1615909B1 (en) | 2008-07-23 |
AR044045A1 (en) | 2005-08-24 |
BRPI0409611A (en) | 2006-04-18 |
SI1615909T1 (en) | 2008-12-31 |
PT1615909E (en) | 2008-10-30 |
JP2006528939A (en) | 2006-12-28 |
US7592347B2 (en) | 2009-09-22 |
WO2004101546A1 (en) | 2004-11-25 |
TW200503713A (en) | 2005-02-01 |
KR20050121268A (en) | 2005-12-26 |
DE602004015269D1 (en) | 2008-09-04 |
AU2004238447B2 (en) | 2008-10-30 |
ES2311152T3 (en) | 2009-02-01 |
AU2004238447A1 (en) | 2004-11-25 |
RU2005136368A (en) | 2006-06-10 |
DK1615909T3 (en) | 2008-11-17 |
CO5700754A2 (en) | 2006-11-30 |
AU2004238447C1 (en) | 2009-06-11 |
EP1615909A1 (en) | 2006-01-18 |
US20070054917A1 (en) | 2007-03-08 |
HK1090634A1 (en) | 2006-12-29 |
ATE402165T1 (en) | 2008-08-15 |
IS8134A (en) | 2005-11-21 |
CA2523431A1 (en) | 2004-11-25 |
HRP20080541T3 (en) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27675A1 (en) | PIPERAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | |
ATE384050T1 (en) | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | |
MA27582A1 (en) | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
MA27482A1 (en) | PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) SUBSTITUTED HEPTANES AS HISTAMINE H1 AND / OR H3 ANTAGONISTS OR REVERSE HISTAMINE H3 ANTAGONISTS | |
DE69816608D1 (en) | 1H-PYRAZOLO [3,4-D] PYRIMIDINE-4,6-DIONE AS INHIBITORS FOR T-CELL REPRODUCTION | |
TW200621716A (en) | Novel compounds | |
MA28289A1 (en) | IMMUNOGLOBULIN | |
ATE440087T1 (en) | 2,4-DIAMINOPYRIMIDENE DERIVATIVES THAT ARE SUITABLE AS INHIBITORS OF PKC-THETA | |
MA29693B1 (en) | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | |
TNSN05104A1 (en) | THIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | |
MA28681B1 (en) | 3-aminocyclopentanecarboxamides useful as modulators of chemokine receptors | |
MA27668A1 (en) | 2,4-DI (PHENYLAMINO) PYRIMIDINES USED TO TREAT NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | |
AP1860A (en) | Aryl fused azapolycyclic compounds. | |
TW200611701A (en) | Novel compounds | |
MY138836A (en) | Quinoline derivatives and their use as 5-ht6 receptor ligands | |
TN2009000551A1 (en) | NEW CHEMICAL COMPOUNDS | |
MA28680B1 (en) | 3-aminocyclopentanecarboxamides useful as modulators of chemokine receptors | |
TW200503710A (en) | Novel compounds | |
MA28241A1 (en) | TRICYCLIC HYDROXYETHYLAMINE INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | |
MA30041B1 (en) | IMMUNOGLOBULIN | |
TNSN98035A1 (en) | ATROPISOMERS OF 3-ARYL-4 (3H) -QUINAZOLINONES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | |
TNSN99155A1 (en) | 1-ARYL-3-ARYLMETHYL-1,8-NAPHTYRIDINE-4 (1H) -ONES NOVELS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
MX2007006754A (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders. | |
TNSN98024A1 (en) | 2-AMINO-6- (2-SUBSTITUE-4-PHENOXY) -SUBSTITUE-PYRIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
TW200502221A (en) | Novel lactams and uses thereof |